ArticlemSphere2025
LINC2781 enhances antiviral immunity against coxsackievirus B5 infection by activating the JAK-STAT pathway and blocking G3BP2-mediated STAT1 degradation.
Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The LncRNA Expression Profile and Regulatory Network of Microsporidian During the Infection of Western Honeybee.Animals : an open access journal from MDPI · 2026Article
- Article
- Research Progress on the Biological Function, Disease-Driving Mechanism and Clinical Targeting Strategies of G3BP2.Molecules (Basel, Switzerland) · 2026Review
- LINC1467 Activates the IPO8-p65 Axis to Restrict Hand, Foot, and Mouth Disease Virus Replication.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Coxsackievirus B5 (CVB5) is a primary causative agent of hand, foot, and mouth disease (HFMD), and some cases are also associated with severe complications through invasion of the central nervous system, resulting in death. Currently, there are no specific antiviral drugs or effective vaccines available for CVB5. Long non-coding RNAs (lncRNAs) have been shown to play significant roles in various diseases. In our research, we identified a novel lncRNA, LINC2781, which is significantly upregulated during CVB5 infection of SH-SY5Y cells. Characteristic analysis showed that LINC2781 is mainly located in the cytoplasm of infected cells, with significantly higher expression in the intestines and the spleen of CVB5-infected mice. Functional studies revealed that LINC2781 activates the JAK-STAT pathway via STAT1, promoting the expression of interferon-stimulated genes (ISGs) and inhibiting CVB5 replication. Mechanistically, LINC2781 directly binds to GTPase-activating protein SH3 domain-binding protein 2 (G3BP2), preventing G3BP2-mediated degradation of STAT1 through ubiquitination. IMPORTANCE: We investigate the role of lncRNA in virus-host interactions and identify a novel cytoplasmic lncRNA, LINC2781, whose expression is upregulated following CVB5 infection. LINC2781 specifically binds to G3BP2, preventing G3BP2 from degrading STAT1, thereby activating the JAK-STAT pathway, promoting the expression of ISGs, and ultimately inhibiting viral replication. Meanwhile, a strong correlation exists between the expression of LINC2781 and CVB5 infection in cells and clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.